Combination treatment for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination treatment for liver cancer that has not spread to other organs. It combines two procedures that deliver chemo directly to the liver (HAIC and TACE) with two medications (apatinib and camrelizumab) that help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- Your liver cancer is at a stage where surgery is not an option or you have chosen not to have surgery.
- Your liver function is good (Child-Pugh score of 7 or less).
- You are able to take care of yourself (ECOG score 0-1) and are expected to live at least 12 weeks.
- You have not had chemoembolization or other local treatments for your liver cancer before.
- You do not have active hepatitis B or C, or you are on antiviral therapy and have low viral levels.
- Your cancer has not spread to other parts of your body (no distant metastasis).
- You do not have a major blockage in the main vein of your liver (portal vein tumor thrombus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study tests two different treatment combinations for liver cancer that cannot be removed with surgery. One group gets a treatment called TACE plus a pill combination, and the other gets TACE plus standard targeted immunotherapy. The goal is to see which approach works better.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.